Longevity · In Clinical Trials
NAD+ Precursors (NMN)
No lawful US pathway
01 · Overview
Nicotinamide mononucleotide (NMN) is a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular metabolism and for enzymes such as sirtuins and PARPs involved in DNA repair. NAD+ availability decreases with age, and in mice orally administered NMN is rapidly used to synthesize NAD+ in tissues (PMID 28068222).
NMN is sold as a dietary supplement and is not an FDA-approved drug.
02 · Research summary & key findings
In a 12-month mouse study, NMN suppressed age-associated weight gain and improved energy metabolism, physical activity, insulin sensitivity, and plasma lipids without obvious toxicity (Mills et al., Cell Metabolism, 2016) (PMID 28068222). A 10-week randomized trial in overweight or obese postmenopausal women with prediabetes found NMN increased muscle insulin sensitivity and insulin signaling (Yoshino et al., Science, 2021) (PMID 33888596). A 2026 meta-analysis of randomized trials found short-term NMN well tolerated but without clear effects on weight, glucose, HbA1c, or lipids (PMID 42514320).
03 · Regulatory status
NAD+ Precursors (NMN) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
NAD+ Precursors (NMN) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 3 FDA-approved compounds in Longevity
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for longevity and healthy ageing?
NAD+ Precursors (NMN) is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on longevity and healthy ageing, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Oral
- Intravenous
- Sublingual
References
- [1]Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice Cell Metab, 2016. PMID 28068222
- [2]Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women Science, 2021. PMID 33888596
- [3]Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis Nutrients, 2026. PMID 42514320
Primary literature
- PubMed: "NAD+ Precursors"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "NAD+ Precursors"
Registered interventional and observational studies, including status and phase.
- PubChem: "NAD+ Precursors"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Longevity
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.